Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib + Cobimetinib/Cetuximab in Solid Tumors
NCT03284502Phase 1Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Belvarafenib in solid tumor (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Percentage of patients with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest up to 3 years, Number of patients with Dose Limiting Toxicities at 28 days and 2 more. Status: unknown.
02
Drugs
Belvarafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03284502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284502.